As was mentioned in class, most of the treatments for
inflammatory bowel disease that were available around the time the review
articles were published focused on treating the downstream effects of
inflammation, rather than preventing it in the first place. That sparked me to
want to find if there was any more recent research done to try to find a drug
that focused on preventing activation of the inflammatory cascade in the first place.
After some research, I came across a drug called Vedolizumab.
In general, inflammatory bowel disease is characterized by chronic inflammation
in the gut. Therefore, a very simple cure for inflammatory bowel disease would be
to just “turn off” the immune system. Obviously this is not a viable treatment,
as it would cause widespread problems throughout the rest of the body. Vedolizumab
takes advantage of the fact that the body is able to selectively send T cells
to the part of the body they are needed. It has been discovered that one of the
main ways the body directs T cells to the gut is using the glycoprotein α4β7. α4β7 is an integral
membrane protein in T cells and when it binds to a molecule called MAdCAM-1, which is located
in the mucosa, the T cell is able to move through the submucosa into the gut.
From there the T cell can contribute to the immune response needed in the GI
tract. Vedolizumab is a monoclonal antibody that is specific for the α4β7 protein. Vedolizumab
is able to bind to α4β7, preventing it from being able to bind to MADCAM-1, and
therefore inhibiting the movement of T cells into the gut. In this way,
Vedolizumab is able to “shut off” the immune response in the gut, while still
allowing the immune system to function in the rest of the body.
I found this to be a fascinating way to go about treating inflammatory
bowel disease. I feel that too often in medicine the focus is on medicating the
effect rather than the cause. As mentioned above, this was also the case in
inflammatory bowel disease; there were medications to mitigate the effects of
the chronic inflammation, but nothing to inhibit the inflammation from occurring
in the first place. Since it goes to the route of the cause of inflammation, I believe that Vedolizumab shows great promise as a
treatment for inflammatory bowel disease. It will be interesting to follow up
on this drug after it has been more extensively tested.
Sources:
Fedyk, E. R., Wyant, T., Yang, L.-L., Csizmadia, V., Burke,
K., Yang, H. and Kadambi, V. J. (2012), Exclusive antagonism of the α4β7
integrin by vedolizumab confirms the gut-selectivity of this pathway in
primates. Inflamm Bowel Dis, 18: 2107–2119. doi: 10.1002/ibd.22940
Feagan BG, et al. Vedolizumab as induction and maintenance
therapy for ulcerative colitis. The New England Journal of Medicine.
2013;369:699.
Sandborn WJ, et al. Vedolizumab as induction and maintenance
therapy for Crohn's disease. The New England Journal of Medicine. 2013;369:711.